Members

Blog Posts

Oncology Precision Medicine Market Analysis, Size, Share, and Forecast 2031

Posted by Prajakta on April 25, 2024 at 8:26am 0 Comments

The Oncology Precision Medicine Market in 2023 is US$ 105.96 billion, and is expected to reach US$ 225.82 billion by 2031 at a CAGR of 9.90%.

FutureWise Research published a report that analyzes Oncology Precision Medicine Market trends to predict the market's growth. The report begins with a description of the business environment and explains the commercial… Continue

The Future of Betting: Trends and Innovations in Online Platforms

Posted by sohail khatri on April 25, 2024 at 8:25am 0 Comments

In the digital age, the landscape of betting has undergone a significant transformation with the rise of online platforms. From traditional sports betting to virtual casinos and beyond, the world of online betting offers a vast array of opportunities for enthusiasts to engage in their favorite pastime from the comfort of their own homes.แทงบอล, we'll explore the various facets of online betting, from its history and evolution to strategies for success and… Continue

Plasma Protease C1-inhibitor Treatment Market Shares, Strategies, and Forecasts Analysis

The vendor landscape of the global market for plasma protease c1-inhibitor treatment market is largely consolidated with a handful of companies collectively accounting for a lion's share in the market and maintaining a tough level of competition, observes Transparency Market Research in a recent report.

Read Report Overview -

https://www.transparencymarketresearch.com/plasma-protease-c1inhibi...

The company Shire plc. held the dominant spot in the market, thanks to its expansive product portfolio and extensive geographical reach. Other leading companies in the market, including CSL Limited, Pharming Group N.V., and Sanquin are focused on expanding their geographical outreach, product portfolios, and startegic collaborations to establish a stronghold on the market.

According to the report, the global plasma protease c1-inhibitor treatment market will exhibit an impressive 20.0% CAGR from 2017 to 2025. Considering that the numbers hold true, the market is expected to rise from a valuation of US$1.5 bn in 2016 to a revenue opportunity of US$7.9 bn by the end of 2025.

Request Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B...

North America Takes Lead; to Retain Dominance as HAE and Prophylaxis Cases Rise

Of the key drug classes used in plasma protease C1-inhibitor treatment covered under the report, the segment of C1-inhibitors accounted for the dominant share in the market in 2016. The wide usage of this drug class for the treatment of conditions such as prophylaxis and acute hereditary angioedema (HAE) is likely to keep their demand steady across the globe.

Geographically, the global plasma protease c1-inhibitor treatment market acquires a large share of its revenue from sales across the North America region. The regional market presents high demand for plasma protease c1-inhibitor treatment owing to the high number of HAE cases in the U.S.

Request for Analysis of COVID-19 Impact on Plasma Protease C1-inhibitor Treatment Market -

https://www.transparencymarketresearch.com/sample/sample.php?flag=c...

Rise in Research Efforts Aimed at Development of Novel C1-inhibitor Drug Classes to Bode Well for Market

The rising awareness regarding the available treatment options for HAE is one of the key factors driving the global plasma protease C1-inhibitor treatment market. Other contributing factors include the steadily expanding pipeline of novel drug classes and formulations, thanks to an increase in investment for the research and development of inhibitor drugs, and the rising prevalence of acute HAE and prophylaxis globally.

The market is also benefitting from the rising practice of prescribing prophylactic treatment procedure for HAE patients, increased focus on the research related to a new route of administering C1-inhibitor medicines, and increased demand for subcutaneous administration of C1-inhibitor drugs in HAE patient.

Make an Enquiry before Buying -

https://www.transparencymarketresearch.com/sample/sample.php?flag=E...

Furthermore, the market could also benefit from the increased availability of C1-inhibitor drugs such as Ruconest in emerging economies with vast unmet needs in the area of HAE and prophylaxis treatment. Research efforts underway aimed at the development of bradykinin B2 receptor antagonist for HAE attack treatment is also likely to work in favor of the market.

More Trending Reports by Transparency Market Research –

Liposuction Equipment Market:

https://www.biospace.com/article/liposuction-equipment-market-incre...

Minimally Invasive Spinal Devices Market:

https://www.biospace.com/article/minimally-invasive-spinal-devices-...

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Rohit Bhisey Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/

Views: 1

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2024   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service